Panakeia Technologies (previously Panakeia AI)
Developing rapid instrument-free diagnostic technologies to reduce the need for multiple lab-based tests.
Currently, cancer diagnosis is an iterative, multi-step process requiring analysis of a tissue biopsy by a pathologist, followed by several lab-based tests (molecular and genetic). These lab-based tests account for 90% of the time and cost associated with diagnosis, and contribute to 44% of pathology delays.
Panakeia’s software can provide pathologists with all the information needed for diagnosis and treatment from initial biopsies – eliminating the need for lab tests.
Clinical research labs focused on cancer research and cancer specialty hospitals and clinics.
UKCA and CE marks achieved
Accepted onto current cohort of DHLA
Website and social media
UN Sustainable Development Goals
Want to connect with Panakeia Technologies?
Fill out the form below and we’ll send an introduction email to you and the founders.
Please note that if you would also like to connect with other King’s20 Ventures, we ask that you fill out the form at the bottom of the page each time so we can send separate intro emails.
As always, we respect your privacy and will not contact you without your consent or share your details.